Ovid Therapeutics Inc (OVID)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,174 | -11,694 | -52,339 | -37,017 | -25,765 |
| Depreciation Amortization | 284 | 136 | 568 | 428 | 282 |
| Accounts payable and accrued liabilities | 1,017 | -107 | 1,750 | -736 | 1,810 |
| Other Working Capital | 2,448 | -1,740 | 2,386 | -1,268 | -1,297 |
| Other Operating Activity | -31,516 | -3,281 | 1,854 | 4,723 | 1,152 |
| Operating Cash Flow | $-30,941 | $-16,686 | $-45,781 | $-33,870 | $-23,818 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 33,179 | 20,207 | 7,557 | 56,072 | 60,426 |
| PPE Investments | -53 | -19 | -40 | -27 | -21 |
| Purchase Of Investment | N/A | N/A | -10,000 | -10,000 | -10,000 |
| Purchase Sale Intangibles | -116 | N/A | -97 | -110 | -110 |
| Other Investing Activity | -116 | 0 | -98 | -110 | -110 |
| Investing Cash Flow | $33,010 | $20,188 | $-2,581 | $45,935 | $50,295 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 584 | 228 | 535 | 502 | 278 |
| Other Financing Activity | 0 | 0 | 30,000 | 0 | 0 |
| Financing Cash Flow | $584 | $228 | $30,535 | $502 | $278 |
| Beginning Cash Position | 28,972 | 28,972 | 46,799 | 46,799 | 46,799 |
| End Cash Position | 31,625 | 32,703 | 28,972 | 59,367 | 73,554 |
| Net Cash Flow | $2,653 | $3,731 | $-17,826 | $12,568 | $26,755 |
| Free Cash Flow | |||||
| Operating Cash Flow | -30,941 | -16,686 | -45,781 | -33,870 | -23,818 |
| Capital Expenditure | -53 | -19 | -40 | -27 | -21 |
| Free Cash Flow | -30,994 | -16,705 | -45,821 | -33,897 | -23,839 |